Seite - 46 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Dawidczyketal. Nanomedicines for cancer therapy Morales-Avila, E., Ferro-Flores,G.,Ocampo-Garcia, B. E.,DeLeon-Rodriguez, L. M., Santos-Cuevas, C. L., Garcia-Becerra, R., et al. (2011).Multimeric system of99mTc-labeledgoldnanoparticlesconjugatedtoc[RGDfK(C)]formolecular imaging of tumor alpha(v)beta(3) expression.Bioconjug. Chem. 22, 913–922. doi:10.1021/bc100551s Mullard,A. (2013).Maturing antibody-drug conjugate pipeline hits 30.Nat. Rev. DrugDiscov.12,329–332.doi:10.1038/nrd4009 Muller,C.,andSchibli,R.(2013).Prospectsinfolatereceptor-targetedradionuclide therapy.Front.Oncol.3:249.doi:10.3389/fonc.2013.00249 Natarajan, A., Gruettner, C., Ivkov, R., Denardo, G. L., Mirick, G., Yuan, A., et al. (2008). NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug. Chem. 19, 1211–1218. doi: 10.1021/bc800015n Naumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., et al. (2013). PRECEDENT: a randomized phase ii trial comparing vintafolide (EC145) and Pegylated LiposomalDoxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J.Clin.Oncol. 31,4400–4406.doi:10.1200/JCO.2013.49.7685 Nicolas, J., Mura, S., Brambilla, D., Mackiewicz, N., and Couvreur, P. (2013). Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem.Soc.Rev.42,1147–1235.doi:10.1039/c2cs35265f Niemeyer, C.M. (2001). Nanoparticles, proteins, and nucleic acids: biotechnol- ogymeetsmaterials science.Angew. Chem. Int. Ed. Engl. 40, 4128–4158. doi: 10.1002/1521-3773(20011119)40:22<4128::AID-ANIE4128>3.0.CO;2-S Novio, F., Simmchen, J., Vazquez-Mera, N., Amorin-Ferre, L., and Ruiz-Molina, D.(2013).Coordinationpolymernanoparticles inmedicine.Coord.Chem.Rev. 257,2839–2847.doi:10.1016/j.ccr.2013.04.022 Ohguchi, Y., Kawano,K.,Hattori, Y., andMaitani, Y. (2008). Selective delivery of folate-PEG-linked, nanoemulsion-loaded aclacinomycinA toKBnasopharyn- gealcellsandxenograft: effectofchain lengthandamountof folate-PEGlinker. J.DrugTarget.16,660–667.doi:10.1080/10611860802201464 Ohno, K., Mori, C., Akashi, T., Yoshida, S., Tago, Y., Tsujii, Y., et al. (2013). Fabricationof contrast agents formagnetic resonance imaging frompolymer- brush-afforded iron oxide magnetic nanoparticles prepared by surface- initiated living radical polymerization.Biomacromolecules 14, 3453–3462. doi: 10.1021/bm400770n Oyewumi, M. O., Yokel, R. A., Jay, M., Coakley, T., andMumper, R. J. (2004). Comparisonofcelluptake,biodistributionandtumorretentionoffolate-coated and PEG-coated gadoliniumnanoparticles in tumor-bearingmice. J. Control. Release95,613–626.doi:10.1016/j.jconrel.2004.01.002 Pack,D.W.,Hoffman,A. S., Pun, S., andStayton, P. S. (2005).Design anddevel- opment of polymers for gene delivery.Nat. Rev.DrugDiscov. 4, 581–593. doi: 10.1038/nrd1775 Paraskar, A., Soni, S., Roy, B., Papa, A. L., and Sengupta, S. (2012). Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy. Nanotechnology23:075103.doi:10.1088/0957-4484/23/7/075103 Park, J., Dvoracek, C., Lee, K. H., Galloway, J. F., Bhang, H. E. C., Pomper, M. G., et al. (2011). CuInSe/ZnS Core/Shell NIR quantum dots for biomedical imaging.Small7,3148–3152.doi:10.1002/smll.201101558 Parker, N., Turk,M. J.,Westrick, E., Lewis, J. D., Low, P. S., and Leamon, C. P. (2005).Folatereceptorexpressionincarcinomasandnormaltissuesdetermined by a quantitative radioligandbinding assay.Anal. Biochem. 338, 284–293. doi: 10.1016/j.ab.2004.12.026 Penate Medina, O., Haikola, M., Tahtinen, M., Simpura, I., Kaukinen, S., Valtanen, H., et al. (2011). Liposomal tumor targeting in drug delivery uti- lizingMMP-2- andMMP-9-binding ligands. J. DrugDeliv. 2011, 160515. doi: 10.1155/2011/160515 Petersen, A. L., Binderup, T., Jolck, R. I., Rasmussen, P., Henriksen, J. R., Pfeifer, A. K., et al. (2012). Positron emission tomography evaluation of somatostatin receptor targeted 64Cu-TATE-liposomes in a human neuroen- docrine carcinoma mouse model. J. Control. Release 160, 254–263. doi: 10.1016/j.jconrel.2011.12.038 Petryayeva,E.,Algar,W.R.,andMedintz,I.L.(2013).Quantumdotsinbioanalysis: a reviewof applications across variousplatforms forfluorescence spectroscopy andimaging.Appl.Spectrosc.67,215–252.doi:10.1366/12-06948 Piscitelli, S. C., Rodvold, K. A., Rushing, D. A., and Tewksbury, D. A. (1993). Pharmacokineticsandpharmacodynamicsofdoxorubicininpatientswithsmall cell lungcancer.Clin.Pharmacol.Ther.53,555–561.doi:10.1038/clpt.1993.69 Poon,Z., Lee, J. A.,Huang, S., Prevost, R. J., andHammond,P.T. (2011).Highly stable, ligand-clustered “patchy”micelle nanocarriers for systemic tumor tar- geting.Nanomedicine7,201–209.doi:10.1016/j.nano.2010.07.008 Prato,M.,Kostarelos,K., andBianco,A. (2008).Functionalizedcarbonnanotubes indrugdesignanddiscovery.Acc.Chem.Res.41,60–68.doi:10.1021/ar700089b Puvanakrishnan,P.,Park, J.,Chatterjee,D.,Krishnan,S., andTunnell, J.W.(2012). Invivo tumor targetingofgoldnanoparticles: effectofparticle typeanddosing strategy. Int. J.Nanomedicine7,1251–1258.doi:10.2147/IJN.S29147 Reddy, L. H., Sharma, R. K., and Murthy, R. R. (2006). Enhanced delivery of etoposide toDalton’s lymphoma inmice throughpolysorbate20micelles.Acta Pharm.56,143–155. Rijcken,C. J., Snel,C. J., Schiffelers, R.M.,VanNostrum,C. F., andHennink,W. E. (2007). Hydrolysable core-crosslinked thermosensitive polymeric micelles: synthesis, characterisationand invivo studies.Biomaterials28,5581–5593.doi: 10.1016/j.biomaterials.2007.08.047 Robinson, J. T., Hong, G. S., Liang, Y. Y., Zhang, B., Yaghi, O. K., andDai, H. J. (2012). InVivofluorescence imaging in the secondnear-infraredwindowwith long circulating carbon nanotubes capable of ultrahigh tumor uptake. J. Am. Chem.Soc.134,10664–10669.doi:10.1021/ja303737a Rong, P. F., Yang, K., Srivastan, A., Kiesewetter, D. O., Yue, X. Y., Wang, F., et al. (2014). Photosensitizer loaded nano-graphene for multimodality imaging guided tumor photodynamic therapy. Theranostics 4, 229–239. doi: 10.7150/thno.8070 Rossin,R.,Pan,D.P. J.,Qi,K.,Turner, J.L., Sun,X.K.,Wooley,K.L., et al. (2005). Cu-64-labeled folate-conjugated shell cross-linked nanoparticles for tumor imaging and radiotherapy: synthesis, radiolabeling, and biologic evaluation. J.Nucl.Med.46,1210–1218. Ruoslahti, E. (1996). RGD and other recognition sequences for integrins.Annu. Rev.CellDev.Biol.12,697–715.doi:10.1146/annurev.cellbio.12.1.697 Sailor, M. J., and Park, J. H. (2012). Hybrid nanoparticles for detection and treatmentofcancer.Adv.Mater.24,3779–3802.doi:10.1002/adma.201200653 Sassoon,I.,andBlanc,V.(2013).Antibody-drugconjugate(ADC)clinicalpipeline: a review.MethodsMol.Biol.1045,1–27.doi:10.1007/978-1-62703-541-5_1 Seynhaeve, A. L. B., Dicheva, B.M., Hoving, S., Koning, G. A., and TenHagen, T. L.M. (2013). Intact Doxil is taken up intracellularly and released doxoru- bicin sequesters in the lysosome: evaluatedby in vitro/in vivo live cell imaging. J.Control.Release172,330–340.doi:10.1016/j.jconrel.2013.08.034 Sheldrake,H.M., andPatterson, L.H. (2009). Function andantagonismofbeta3 integrins in the development of cancer therapy.Curr. Cancer Drug Targets 9, 519–540.doi:10.2174/156800909788486713 Shi, S. X., Yang, K., Hong, H., Valdovinos, H. F., Nayak, T. R., Zhang, Y., et al. (2013). Tumor vasculature targeting and imaging in living mice with reduced graphene oxide. Biomaterials 34, 3002–3009. doi: 10.1016/j.biomaterials.2013.01.047 Shiraishi, K., Kawano, K., Minowa, T., Maitani, Y., and Yokoyama, M. (2009). Preparation and in vivo imaging of PEG-poly(L-lysine)-based poly- meric micelle MRI contrast agents. J. Control. Release 136, 14–20. doi: 10.1016/j.jconrel.2009.01.010 Sievers,E.L.,andSenter,P.D.(2013).Antibody-drugconjugates incancertherapy. Annu.Rev.Med.64,15–29.doi:10.1146/annurev-med-050311-201823 Silverman, J. A., andDeitcher, S. R. (2013).Marqibo(R) (vincristine sulfate lipo- some injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Cancer Chemother. Pharmacol. 71, 555–564. doi: 10.1007/s00280- 012-2042-4 Soundararajan,A.,Bao,A.,Phillips,W.T.,Perez,R., andGoins,B.A. (2009). [Re- 186]Liposomaldoxorubicin (Doxil): in vitro stability, pharmacokinetics, imag- ingandbiodistribution inaheadandnecksquamouscell carcinomaxenograft model.Nucl.Med.Biol.36,515–524.doi:10.1016/j.nucmedbio.2009.02.004 Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., et al. (2005). Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and pacli- taxel formulated inCremophor (Taxol).Clin. Cancer Res. 11, 4136–4143. doi: 10.1158/1078-0432.CCR-04-2291 Steichen,S.D.,Caldorera-Moore,M.,andPeppas,N.A.(2012).Areviewofcurrent nanoparticleandtargetingmoieties for thedeliveryofcancer therapeutics.Eur. J.Pharm.Sci.48,416–427.doi:10.1016/j.ejps.2012.12.006 Steinmetz,N.F.(2010).Viralnanoparticlesasplatformsfornext-generationthera- peuticsandimagingdevices.Nanomed.Nanotechnol.Biol.Med.6,634–641.doi: 10.1016/j.nano.2010.04.005 Frontiers inChemistry | ChemicalEngineering August2014 |Volume2 |Article69 | 46